Despite being a rare disease impacting less than a million people worldwide, gMG treatment is an increasingly crowded market, ...

After UK Health Secretary Wes Streeting sent a letter to the pharma industry, warning that he would withdraw from ...

The positive data from the Phase 3 Denali trial showed that NCX 470, a nitric oxide-donating bimatoprost eyedrop formulation, ...

The Emeryville, California-based biotech has just released topline results from a phase 1/2 head-to-head study comparing its ...

Iterum Therapeutics has become the first drugmaker to bring an oral antibiotic in the penem class to market in the US, ...

Among the plans will be greater first-line use of SGLT-2 inhibitors or 'gliflozin' drugs, which are mainly used second-line ...

And while pharma marketing agencies are embracing AI like everyone else, most are using AI tools on a case-by-case basis to ...

Novo Nordisk has reduced the price of its two semaglutide-based therapies – Ozempic for diabetes and Wegovy for obesity – to ...

Johnson & Johnson has filled in some of the details of its $55 billion investment in US facilities announced earlier this ...

Mindler has taken ownership of the UK company, which has been providing digitally delivered talking therapies to the NHS for ...

Shares in Viking Therapeutics have lost more than 40% of their value after it reported phase 2 results that showed that its ...

Ionis has won an FDA green light for an RNA-based hereditary angioedema (HAE) treatment, Dawnzera, that can be ...